Text Size
323 studies found for:    "primary myelofibrosis"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis (PMF);   Post Polycythemia Myelofibrosis (PPV MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Myelofibrosis;   Post Polycythemia Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
2 Recruiting Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Conditions: Primary Myelofibrosis (PMF);   Post Polycythaemia Myelofibrosis (PPV MF);   Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Intervention: Drug: INC424
3 Active, not recruiting A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Conditions: Myelofibrosis With Myeloid Metaplasia;   Myeloid Metaplasia;   Myelofibrosis
Interventions: Drug: Pomalidomide;   Drug: Prednisone;   Drug: Placebo
4 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
5 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
6 Recruiting Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
Conditions: Idiopathic Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis;   Post Polycythemia-Vera Myelofibrosis
Interventions: Drug: panobinostat;   Drug: ruxolitinib
7 Active, not recruiting Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
8 Completed Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
9 Recruiting Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis;   Post-Polycythemic Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: NS-018
10 Completed Anti-TGF-beta Therapy in Patients With Myelofibrosis
Conditions: Myelofibrosis;   Primary Myelofibrosis;   Post-polycythemia Vera Related Myelofibrosis;   Post-essential Thrombocythemia Related Myelofibrosis
Intervention: Biological: monoclonal antibody to TGF-beta
11 Active, not recruiting LBH589 (Panobinostat) for the Treatment of Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Related Myelofibrosis;   Post-Essential Thrombocythemia Related Myelofibrosis
Intervention: Drug: LBH589
12 Completed Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Polycythemia Vera, Post-Polycythemic Myelofibrosis
Intervention: Drug: Ruxolitinib
13 Recruiting Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
14 Recruiting An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Fibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
15 Active, not recruiting Safety Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
16 Completed A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Conditions: Myelofibrosis;   Myeloid Metaplasia;   Agnogenic Myeloid Metaplasia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Imatinib mesylate
17 Recruiting Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Conditions: Anemia;   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: ruxolitinib phosphate;   Drug: danazol
18 Recruiting Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Intervention: Drug: imetelstat sodium
19 Withdrawn Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Conditions: Primary Myelofibrosis;   Primary Pulmonary Hypertension;   Secondary Myelofibrosis;   Pulmonary Arterial Hypertension
Intervention:
20 Completed A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
Conditions: Myelofibrosis;   Myeloid Metaplasia
Intervention: Drug: zoledronic acid
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years